AstraZeneca, FibroGen Plan New Roxadustat Filings, But CV Data Confuse Investors
Confusion over top-line pooled cardiovascular Phase III safety data on anemia therapy roxadustat caused shares in AstraZeneca and FibroGen to slide on 9 May, but analysts later said the negative reaction was overdone.
You may also be interested in...
The drug major's Q2 sales soared past consensus forecasts, driven by its three soon-to-be oncology blockbusters – Tagrisso, Imfinzi and Lynparza.
AstraZeneca has presented more data on Farxiga at the American Diabetes Association meeting which should help the SGLT2 inhibitor in its battles with Jardiance and Invokana.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.